| Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer C Feig, JO Jones, M Kraman, RJB Wells, A Deonarine, DS Chan, ... Proceedings of the National Academy of Sciences 110 (50), 20212-20217, 2013 | 2016 | 2013 |
| Capecitabine as adjuvant treatment for stage III colon cancer C Twelves, A Wong, MP Nowacki, M Abt, H Burris III, A Carrato, J Cassidy, ... New England Journal of Medicine 352 (26), 2696-2704, 2005 | 1747 | 2005 |
| Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer MA Jacobetz, DS Chan, A Neesse, TE Bapiro, N Cook, KK Frese, C Feig, ... Gut 62 (1), 112-120, 2013 | 1214 | 2013 |
| Inhibition of cancer cell growth by ruthenium (II) arene complexes RE Morris, RE Aird, P del Socorro Murdoch, H Chen, J Cummings, ... Journal of medicinal chemistry 44 (22), 3616-3621, 2001 | 928 | 2001 |
| In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer RE Aird, J Cummings, AA Ritchie, M Muir, RE Morris, H Chen, PJ Sadler, ... British journal of cancer 86 (10), 1652-1657, 2002 | 752 | 2002 |
| Combenefit: an interactive platform for the analysis and visualization of drug combinations GY Di Veroli, C Fornari, D Wang, S Mollard, JL Bramhall, FM Richards, ... Bioinformatics 32 (18), 2866-2868, 2016 | 699 | 2016 |
| Structure− activity relationships for cytotoxic ruthenium (II) arene complexes containing N, N-, N, O-, and O, O-chelating ligands A Habtemariam, M Melchart, R Fernández, S Parsons, IDH Oswald, ... Journal of medicinal chemistry 49 (23), 6858-6868, 2006 | 556 | 2006 |
| nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer KK Frese, A Neesse, N Cook, TE Bapiro, MP Lolkema, DI Jodrell, ... Cancer discovery 2 (3), 260-269, 2012 | 490 | 2012 |
| Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. DI Jodrell, MJ Egorin, RM Canetta, P Langenberg, EP Goldbloom, ... Journal of clinical oncology 10 (4), 520-528, 1992 | 470 | 1992 |
| Oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial W Scheithauer, J McKendrick, S Begbie, M Borner, WI Burns, HA Burris, ... Annals of Oncology 14 (12), 1735-1743, 2003 | 363 | 2003 |
| Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity TR Flint, T Janowitz, CM Connell, EW Roberts, AE Denton, AP Coll, ... Cell metabolism 24 (5), 672-684, 2016 | 362 | 2016 |
| Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer LW Seymour, DR Ferry, DJ Kerr, D Rea, M Whitlock, R Poyner, C Boivin, ... International journal of oncology 34 (6), 1629-1636, 2009 | 354 | 2009 |
| Controlling ligand substitution reactions of organometallic complexes: Tuning cancer cell cytotoxicity F Wang, A Habtemariam, EPL van der Geer, R Fernández, M Melchart, ... Proceedings of the National Academy of Sciences 102 (51), 18269-18274, 2005 | 342 | 2005 |
| Tuning the reactivity of osmium (II) and ruthenium (II) arene complexes under physiological conditions AFA Peacock, A Habtemariam, R Fernández, V Walland, FPA Fabbiani, ... Journal of the American Chemical Society 128 (5), 1739-1748, 2006 | 305 | 2006 |
| CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer A Neesse, KK Frese, TE Bapiro, T Nakagawa, MD Sternlicht, TW Seeley, ... Proceedings of the National Academy of Sciences 110 (30), 12325-12330, 2013 | 281 | 2013 |
| Loss of P53 function activates JAK2–STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient … SM Wörmann, L Song, J Ai, KN Diakopoulos, MU Kurkowski, K Görgülü, ... Gastroenterology 151 (1), 180-193. e12, 2016 | 272 | 2016 |
| A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer I Chau, AR Norman, D Cunningham, D Tait, PJ Ross, T Iveson, M Hill, ... Annals of Oncology 16 (4), 549-557, 2005 | 236 | 2005 |
| A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer ER Brown, KA Charles, SA Hoare, RL Rye, DI Jodrell, RE Aird, R Vora, ... Annals of oncology 19 (7), 1340-1346, 2008 | 231 | 2008 |
| CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype JB Candido, JP Morton, P Bailey, AD Campbell, SA Karim, T Jamieson, ... Cell reports 23 (5), 1448-1460, 2018 | 226 | 2018 |
| CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response D Biasci, M Smoragiewicz, CM Connell, Z Wang, Y Gao, ... Proceedings of the National Academy of Sciences 117 (46), 28960-28970, 2020 | 218 | 2020 |
